Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$144.13 USD
-1.50 (-1.03%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $144.02 -0.11 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 21 - 40 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for NBIX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Setting Expectations For the NBI-921352 FOS Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Crinecerfont Wins Over Androgens Across Patient Age Groups; Reiterate Buy and PT Up to $150
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Pediatric Phase 3 CAHtalyst Offers Another Pipeline Win
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
With Crinecerfont?s Success, Neurocrine Expands Footprint to Endocrinology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Adult Phase 3 CAHtalyst Hits; Pediatric Data Remains On Track For Early 4Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza?s New Approval, Has an Edge Over Competitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Setting Expectations For the Adult CAH Program; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Beat and Raise as Ingrezza Strength Remains in Effect
Provider: Wedbush Securities Inc.
Analyst: CHICO L